[Biolojic in Business Wire] First U.S. patient dosed in Aulos Bioscience’s Phase 1/2 clinical trial of AU-007, a novel IL-2 therapeutic for the treatment of solid tumors

LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that the first patient has been dosed in the United States in its Phase 1/2 clinical trial evaluating AU-007 for the treatment of solid tumors.

Read more here.